NCT03791775

Brief Summary

Hemorrhoidal disease (HD) is one of the oldest and most common proctologic diseases that has been described with an estimated prevalence between 4.4% and 86%. Despite the proposal of three mechanisms that might underlie haemorrhoidal development - the varicose vein theory, the vascular hyperplasia theory and the sliding anal-lining theory, the exact pathophysiology of symptomatic hemorrhoid disease is poorly understood. HD seems to be the most common cause for rectal bleeding, or hematochezia, and the second most frequent cause for severe rectorrhagia after diverticulitis. The blood is bright red and coats the stool at the end of defection. Other symptoms include pain, mucous discharge, itching or the sensation of tissue prolapse. The most widely accepted classification is the Goligher classification:

  • Grade I: hemorrhoids bleed but do not prolapse out of the anal canal;
  • Grade II: hemorrhoidal cushions prolapse outside of the anal canal on straining or during bowel movements, but reduce spontaneously;
  • Grade III: hemorrhoidal cushions prolapse outside the anal canal on straining and require manual reduction;
  • Grade IV: hemorrhoidal prolapse is irreducible even with manipulation

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
183

participants targeted

Target at P75+ for phase_2

Timeline
Completed

Started Jan 2019

Shorter than P25 for phase_2

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

December 29, 2018

Completed
4 days until next milestone

Study Start

First participant enrolled

January 2, 2019

Completed
1 day until next milestone

First Posted

Study publicly available on registry

January 3, 2019

Completed
5 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

June 2, 2019

Completed
1 year until next milestone

Study Completion

Last participant's last visit for all outcomes

June 2, 2020

Completed
Last Updated

September 17, 2021

Status Verified

September 1, 2021

Enrollment Period

5 months

First QC Date

December 29, 2018

Last Update Submit

September 11, 2021

Conditions

Keywords

HemorrhoidsSclerotherapyPolidocanol 3%Non-surgical treatments

Outcome Measures

Primary Outcomes (1)

  • Success Rate 1

    To establish the success rate after one sclerotherapy session, in terms of complete resolution of bleeding episodes one week after the injection Bleeding will be assessed using both the Hemorrhoidal Disease Symptoms Score and the Giamundo score. Rørvik HD et al (2019) Hemorrhoidal Disease Symptom Score and Short Health ScaleHD: New Tools to Evaluate Symptoms and Health-Related Quality of Life in Hemorrhoidal Disease. Dis Colon Rectum; 62:333-342 Giamundo et al (2018) Doppler-guided hemorrhoidal dearterialization with laser (HeLP): a prospective analysis of data from a multicenter trial. Tech Coloproctol; 25:635-643

    12 months follow-up

Secondary Outcomes (5)

  • Success Rate 2

    12 months follow-up

  • Number of outpatient sessions

    12 months follow-up

  • Rate of complications - adverse events

    6 months follow-up

  • Quality of Life

    12 months follow-up

  • To establish the average time required to reach autonomy

    12 months follow-up

Study Arms (1)

Polidocanol 3% Foam

EXPERIMENTAL

Patients enrolled in the study, according to the inclusion and exclusion criteria, will undergo sclerotherapy performed with polidocanol foam (Atossisclerol® 3%, Chemische Fabrik Kreussler \& Co. GmbH, Wiesbaden, Germany).

Drug: Polidocanol foam (Atossisclerol® 3%)

Interventions

The procedure will be performed in the Sims position or lithotomy position. A modified Blonde-Blanchard technique will be adopted, with the tangential injection of polidocanol foam into the submucosa of the apex of each hemorrhoidal pile, without exceeding three piles, and using a self-lighting open-ended anoscope and a 20-G needle in order to reduce bleeding

Polidocanol 3% Foam

Eligibility Criteria

Age18 Years - 75 Years
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Patients above 18 and below 75 years of age with a confirmed diagnosis of second-degree HD (proctological examination, proctoscopy and, if required, colonoscopy)
  • Patients who report persistent perianal bleeding as a typical symptom of second-degree HD
  • Informed consent from each patient must be obtained
  • Participating centres will be asked to confirm that they have gained formal approval at their site

You may not qualify if:

  • Previous anal surgical procedures
  • Previous sclerotherapy or rubber band ligation in the last 12 months
  • Positive pregnancy test
  • Patients with inability to return for postoperative control visits, to sign the informed consent or to fill out the required clinical diary
  • Breast-feeding
  • Known allergy to polidocanol
  • Acute perianal thrombosis
  • Anal fistula
  • Anal fissure
  • Proctitis
  • Fecal incontinence
  • Coagulation disorders
  • Anticoagulant therapy
  • Known HBV, HCV and HIV infection
  • Acite Crohn's disease or Ulcerative colitis
  • +4 more criteria

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

University of Catanzaro

Catanzaro, 88100, Italy

Location

Related Publications (47)

  • Akerud L (1995) Sclerotherapy of haemorrhoids: a prospective randomised trial of polidocanol and phenol in oil. Coloproctology 17:73-86

    BACKGROUND
  • Moser KH (2007) Evaluation of the efficacy and safety of polidocanol foam in the sclerotherapy of first degree bleeding haemorrhoids. Phlebol Rev (Przeglad Flebologiczny) 15:103-106

    BACKGROUND
  • Blanchard CE (1928) Textbook of ambulant proctology p. 134. Medical Success Press, Youngstown Ohio

    BACKGROUND
  • Gallo G, Sacco R, Sammarco G (2018) Epidemiology of Hemorrhoidal Disease. In: Hemorrhoids. Coloproctology (eds Ratto C, Parello A, Litta F), vol 2. Cham: Springer pp. 3-7

    BACKGROUND
  • Thomson WH. The nature of haemorrhoids. Br J Surg. 1975 Jul;62(7):542-52. doi: 10.1002/bjs.1800620710.

  • Aigner F, Bodner G, Gruber H, Conrad F, Fritsch H, Margreiter R, Bonatti H. The vascular nature of hemorrhoids. J Gastrointest Surg. 2006 Jul-Aug;10(7):1044-50. doi: 10.1016/j.gassur.2005.12.004.

  • Burkitt DP. Varicose veins, deep vein thrombosis, and haemorrhoids: epidemiology and suggested aetiology. Br Med J. 1972 Jun 3;2(5813):556-61. doi: 10.1136/bmj.2.5813.556.

  • Gralnek IM, Ron-Tal Fisher O, Holub JL, Eisen GM. The role of colonoscopy in evaluating hematochezia: a population-based study in a large consortium of endoscopy practices. Gastrointest Endosc. 2013 Mar;77(3):410-8. doi: 10.1016/j.gie.2012.10.025. Epub 2013 Jan 5.

  • Nikpour S, Ali Asgari A. Colonoscopic evaluation of minimal rectal bleeding in average-risk patients for colorectal cancer. World J Gastroenterol. 2008 Nov 14;14(42):6536-40. doi: 10.3748/wjg.14.6536.

  • Wong RF, Khosla R, Moore JH, Kuwada SK. Consider colonoscopy for young patients with hematochezia. J Fam Pract. 2004 Nov;53(11):879-84.

  • Mehanna D, Platell C. Investigating chronic, bright red, rectal bleeding. ANZ J Surg. 2001 Dec;71(12):720-2. doi: 10.1046/j.1445-1433.2001.02277.x.

  • Gayer C, Chino A, Lucas C, Tokioka S, Yamasaki T, Edelman DA, Sugawa C. Acute lower gastrointestinal bleeding in 1,112 patients admitted to an urban emergency medical center. Surgery. 2009 Oct;146(4):600-6; discussion 606-7. doi: 10.1016/j.surg.2009.06.055.

  • Newman J, Fitzgerald JE, Gupta S, von Roon AC, Sigurdsson HH, Allen-Mersh TG. Outcome predictors in acute surgical admissions for lower gastrointestinal bleeding. Colorectal Dis. 2012 Aug;14(8):1020-6. doi: 10.1111/j.1463-1318.2011.02824.x.

  • Goligher JC. Cryosurgery for hemorrhoids. Dis Colon Rectum. 1976 Apr;19(3):213-8. doi: 10.1007/BF02590905. No abstract available.

  • Trompetto M, Clerico G, Cocorullo GF, Giordano P, Marino F, Martellucci J, Milito G, Mistrangelo M, Ratto C. Erratum to: Evaluation and management of hemorrhoids: Italian society of colorectal surgery (SICCR) consensus statement. Tech Coloproctol. 2016 Mar;20(3):201. doi: 10.1007/s10151-015-1416-0. No abstract available.

  • Awad AE, Soliman HH, Saif SA, Darwish AM, Mosaad S, Elfert AA. A prospective randomised comparative study of endoscopic band ligation versus injection sclerotherapy of bleeding internal haemorrhoids in patients with liver cirrhosis. Arab J Gastroenterol. 2012 Jun;13(2):77-81. doi: 10.1016/j.ajg.2012.03.008. Epub 2012 Apr 24.

  • Forlini A, Manzelli A, Quaresima S, Forlini M. Long-term result after rubber band ligation for haemorrhoids. Int J Colorectal Dis. 2009 Sep;24(9):1007-10. doi: 10.1007/s00384-009-0698-y. Epub 2009 Apr 23.

  • Kanellos I, Goulimaris I, Christoforidis E, Kelpis T, Betsis D. A comparison of the simultaneous application of sclerotherapy and rubber band ligation, with sclerotherapy and rubber band ligation applied separately, for the treatment of haemorrhoids: a prospective randomized trial. Colorectal Dis. 2003 Mar;5(2):133-8. doi: 10.1046/j.1463-1318.2003.00395.x.

  • Fukuda A, Kajiyama T, Arakawa H, Kishimoto H, Someda H, Sakai M, Tsunekawa S, Chiba T. Retroflexed endoscopic multiple band ligation of symptomatic internal hemorrhoids. Gastrointest Endosc. 2004 Mar;59(3):380-4. doi: 10.1016/s0016-5107(03)02818-9.

  • Bernal JC, Enguix M, Lopez Garcia J, Garcia Romero J, Trullenque Peris R. Rubber-band ligation for hemorrhoids in a colorectal unit. A prospective study. Rev Esp Enferm Dig. 2005 Jan;97(1):38-45. doi: 10.4321/s1130-01082005000100005. English, Spanish.

  • Gupta PJ, Heda PS, Kalaskar S. Randomized controlled study between suture ligation and radio wave ablation and suture ligation of grade III symptomatic hemorrhoidal disease. Int J Colorectal Dis. 2009 Apr;24(4):455-60. doi: 10.1007/s00384-008-0579-9. Epub 2008 Sep 7.

  • Iyer VS, Shrier I, Gordon PH. Long-term outcome of rubber band ligation for symptomatic primary and recurrent internal hemorrhoids. Dis Colon Rectum. 2004 Aug;47(8):1364-70. doi: 10.1007/s10350-004-0591-2.

  • Wehrmann T, Riphaus A, Feinstein J, Stergiou N. Hemorrhoidal elastic band ligation with flexible videoendoscopes: a prospective, randomized comparison with the conventional technique that uses rigid proctoscopes. Gastrointest Endosc. 2004 Aug;60(2):191-5. doi: 10.1016/s0016-5107(04)01551-2.

  • Beattie GC, Rao MM, Campbell WJ. Secondary haemorrhage after rubber band ligation of haemorrhoids in patients taking clopidogrel--a cautionary note. Ulster Med J. 2004 Nov;73(2):139-41. No abstract available.

  • Chau NG, Bhatia S, Raman M. Pylephlebitis and pyogenic liver abscesses: a complication of hemorrhoidal banding. Can J Gastroenterol. 2007 Sep;21(9):601-3. doi: 10.1155/2007/106946.

  • Tejirian T, Abbas MA. Bacterial endocarditis following rubber band ligation in a patient with a ventricular septal defect: report of a case and guideline analysis. Dis Colon Rectum. 2006 Dec;49(12):1931-3. doi: 10.1007/s10350-006-0769-x.

  • Sim HL, Tan KY, Poon PL, Cheng A, Mak K. Life-threatening perineal sepsis after rubber band ligation of haemorrhoids. Tech Coloproctol. 2009 Jun;13(2):161-4. doi: 10.1007/s10151-008-0435-5. Epub 2008 Aug 5.

  • Yano T, Asano M, Tanaka S, Oda N, Matsuda Y. Prospective study comparing the new sclerotherapy and hemorrhoidectomy in terms of therapeutic outcomes at 4 years after the treatment. Surg Today. 2014 Mar;44(3):449-53. doi: 10.1007/s00595-013-0564-y. Epub 2013 Mar 30.

  • Miyamoto H, Asanoma M, Miyamoto H, Shimada M. ALTA injection sclerosing therapy:non-excisional treatment of internal hemorrhoids. Hepatogastroenterology. 2012 Jan-Feb;59(113):77-80. doi: 10.5754/hge11089.

  • Tokunaga Y, Sasaki H. Impact of less invasive treatments including sclerotherapy with a new agent and hemorrhoidopexy for prolapsing internal hemorrhoids. Int Surg. 2013 Jul-Sep;98(3):210-3. doi: 10.9738/INTSURG-D-13-00030.1.

  • Moser KH, Mosch C, Walgenbach M, Bussen DG, Kirsch J, Joos AK, Gliem P, Sauerland S. Efficacy and safety of sclerotherapy with polidocanol foam in comparison with fluid sclerosant in the treatment of first-grade haemorrhoidal disease: a randomised, controlled, single-blind, multicentre trial. Int J Colorectal Dis. 2013 Oct;28(10):1439-47. doi: 10.1007/s00384-013-1729-2. Epub 2013 Jun 18.

  • Takano M, Iwadare J, Ohba H, Takamura H, Masuda Y, Matsuo K, Kanai T, Ieda H, Hattori Y, Kurata S, Koganezawa S, Hamano K, Tsuchiya S. Sclerosing therapy of internal hemorrhoids with a novel sclerosing agent. Comparison with ligation and excision. Int J Colorectal Dis. 2006 Jan;21(1):44-51. doi: 10.1007/s00384-005-0771-0. Epub 2005 Apr 21.

  • Yano T, Nogaki T, Asano M, Tanaka S, Kawakami K, Matsuda Y. Outcomes of case-matched injection sclerotherapy with a new agent for hemorrhoids in patients treated with or without blood thinners. Surg Today. 2013 Aug;43(8):854-8. doi: 10.1007/s00595-012-0365-8. Epub 2012 Oct 10.

  • Bullock N. Impotence after sclerotherapy of haemorrhoids: case reports. BMJ. 1997 Feb 8;314(7078):419. doi: 10.1136/bmj.314.7078.419. No abstract available.

  • Schulte T, Fandrich F, Kahlke V. Life-threatening rectal necrosis after injection sclerotherapy for haemorrhoids. Int J Colorectal Dis. 2008 Jul;23(7):725-6. doi: 10.1007/s00384-007-0402-z. Epub 2007 Nov 28. No abstract available.

  • Yang P, Wang YJ, Li F, Sun JB. Hemorrhoid sclerotherapy with the complication of abdominal compartment syndrome: report of a case. Chin Med J (Engl). 2011 Jun;124(12):1919-20.

  • Lobascio P, Minafra M, Laforgia R, Giove C, Trompetto M, Gallo G. The use of sclerotherapy with polidocanol foam in the treatment of second-degree haemorrhoidal disease - a video vignette. Colorectal Dis. 2019 Feb;21(2):244-245. doi: 10.1111/codi.14498. Epub 2018 Dec 15. No abstract available.

  • Namasivayam J, Payne D, Maguire D. Prostatic abscess following injection of internal haemorrhoids. Clin Radiol. 2000 Jan;55(1):67-8. doi: 10.1053/crad.1999.0066. No abstract available.

  • Barwell J, Watkins RM, Lloyd-Davies E, Wilkins DC. Life-threatening retroperitoneal sepsis after hemorrhoid injection sclerotherapy: report of a case. Dis Colon Rectum. 1999 Mar;42(3):421-3. doi: 10.1007/BF02236364.

  • Kaman L, Aggarwal S, Kumar R, Behera A, Katariya RN. Necrotizing fascitis after injection sclerotherapy for hemorrhoids: report of a case. Dis Colon Rectum. 1999 Mar;42(3):419-20. doi: 10.1007/BF02236363.

  • Wollmann JC. The history of sclerosing foams. Dermatol Surg. 2004 May;30(5):694-703; discussion 703. doi: 10.1111/j.1524-4725.2004.30208.x.

  • Yamaki T, Nozaki M, Iwasaka S. Comparative study of duplex-guided foam sclerotherapy and duplex-guided liquid sclerotherapy for the treatment of superficial venous insufficiency. Dermatol Surg. 2004 May;30(5):718-22; discussion 722. doi: 10.1111/j.1524-4725.2004.30202.x.

  • Rabe E, Otto J, Schliephake D, Pannier F. Efficacy and safety of great saphenous vein sclerotherapy using standardised polidocanol foam (ESAF): a randomised controlled multicentre clinical trial. Eur J Vasc Endovasc Surg. 2008 Feb;35(2):238-45. doi: 10.1016/j.ejvs.2007.09.006. Epub 2007 Nov 7.

  • Ouvry P, Allaert FA, Desnos P, Hamel-Desnos C. Efficacy of polidocanol foam versus liquid in sclerotherapy of the great saphenous vein: a multicentre randomised controlled trial with a 2-year follow-up. Eur J Vasc Endovasc Surg. 2008 Sep;36(3):366-70. doi: 10.1016/j.ejvs.2008.04.010. Epub 2008 Jun 3.

  • BARRON J. Office ligation of internal hemorrhoids. Am J Surg. 1963 Apr;105:563-70. doi: 10.1016/0002-9610(63)90332-5. No abstract available.

  • Rorvik HD, Styr K, Ilum L, McKinstry GL, Dragesund T, Campos AH, Brandstrup B, Olaison G. Hemorrhoidal Disease Symptom Score and Short Health ScaleHD: New Tools to Evaluate Symptoms and Health-Related Quality of Life in Hemorrhoidal Disease. Dis Colon Rectum. 2019 Mar;62(3):333-342. doi: 10.1097/DCR.0000000000001234.

  • Giamundo P, Braini A, Calabro' G, Crea N, De Nardi P, Fabiano F, Lippa M, Mastromarino A, Tamburini AM. Doppler-guided hemorrhoidal dearterialization with laser (HeLP): a prospective analysis of data from a multicenter trial. Tech Coloproctol. 2018 Aug;22(8):635-643. doi: 10.1007/s10151-018-1839-5. Epub 2018 Aug 29.

MeSH Terms

Conditions

Hemorrhoids

Condition Hierarchy (Ancestors)

Rectal DiseasesIntestinal DiseasesGastrointestinal DiseasesDigestive System DiseasesVascular DiseasesCardiovascular Diseases

Study Officials

  • Gaetano Gallo, MD

    Department of Medical and Surgical Sciences, University of Catanzaro, Catanzaro 88100, Italy

    PRINCIPAL INVESTIGATOR

Study Design

Study Type
interventional
Phase
phase 2
Allocation
NA
Masking
NONE
Purpose
TREATMENT
Intervention Model
SINGLE GROUP
Model Details: Patients enrolled in the study, according to the inclusion and exclusion criteria, will undergo sclerotherapy performed with polidocanol foam (Atossisclerol® 3%, Chemische Fabrik Kreussler \& Co. GmbH, Wiesbaden, Germany). The procedure will be performed in the Sims position or lithotomy position. A modified Blonde-Blanchard technique will be adopted, with the tangential injection of polidocanol foam into the submucosa of the apex of each hemorrhoidal pile, without exceeding three piles, and using a self-lighting open-ended anoscope and a 20-G needle in order to reduce bleeding
Sponsor Type
NETWORK
Responsible Party
SPONSOR

Study Record Dates

First Submitted

December 29, 2018

First Posted

January 3, 2019

Study Start

January 2, 2019

Primary Completion

June 2, 2019

Study Completion

June 2, 2020

Last Updated

September 17, 2021

Record last verified: 2021-09

Locations